A comprehensive view of Illnesses/Symptoms/Conditions. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Morningstar assigns AstraZeneca with US$74 fair value estimate, indicating 12% upside, as it's developing several products with blockbuster potential; recently launched drugs Tagrisso, Imfinzi are well-positioned based on efficacy in hard-to-treat cancers
Published: November 23, 2022 by Gwinnett Daily Post
Fitch: GSK's Q3 revenues up 18% year-over-year, but boon expected to shrink as COVID-related sales lower over coming quarters; vaccines business performing well, and FDA approval of company's RSV vaccine for older adults will prove lucrative in H2 2023
Published: November 15, 2022 by Fitch Solutions Sector Intelligence
GSK announces positive results in Phase 2 study showing its investigational tuberculosis medicine GSK3036656 is well-tolerated and shows early effectiveness at a low daily dose for 14 days
Published: November 14, 2022 by U.S. Regulated Equity Markets (Alternative Disclosure) via PUBT
GSK updates prescribing information for the ovarian cancer drug Zejula, limiting use to second-line maintenance therapy only to patients with certain mutation types; change was made at the request of FDA following review of Phase 3 clinical results
Published: November 14, 2022 by PharmaBiz (India)
AstraZeneca and Daiichi Sankyo’s Enhertu injection recommended for approval in the EU as a treatment for certain type of gastric cancer; drug is currently approved in the US
Published: November 14, 2022 by AstraZeneca AB

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count